Toxicology – Antifungal Medications

Core Concept

Antifungal medications are a diverse group, so there is no single antifungal toxidrome. Toxicity depends strongly on the drug class, route, duration of exposure, renal/hepatic function, and interacting medications.

Important groups include:

• Polyenes – amphotericin B, nystatin
• Azoles – fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, ketoconazole, and topical imidazoles
• Antimetabolite – flucytosine
• Echinocandins – caspofungin, micafungin, anidulafungin
• Allylamines – terbinafine

Major toxicologic concerns include:

• Amphotericin B → nephrotoxicity and electrolyte disturbances
• Flucytosine → bone-marrow suppression and GI toxicity
• Systemic azoles → hepatotoxicity, drug interactions, and agent-specific QT effects
• Most topical/vaginal antifungals → predominantly local or mild GI effects after accidental exposure

There is generally no specific antidote.

1. Amphotericin B

Amphotericin B is a polyene antifungal used for serious systemic fungal infections.

It binds fungal membrane ergosterol, forming membrane pores and disrupting cellular integrity.

Unfortunately, amphotericin can also interact with mammalian cell membranes and produce significant toxicity.

Amphotericin B – Major Toxicities

The principal adverse effects are:

• Nephrotoxicity
• Potassium wasting
• Magnesium wasting
• Infusion-related reactions
• Anemia
• Less commonly severe cardiovascular effects

Toxicity is more important after parenteral exposure than accidental oral ingestion because conventional amphotericin B is poorly absorbed from the GI tract.

Amphotericin B Nephrotoxicity

Amphotericin can cause:

• Renal vasoconstriction
• Reduced GFR
• Direct tubular injury

Clinical consequences include:

• Rising creatinine
• Azotemia
• Renal potassium wasting
• Renal magnesium wasting
• Renal tubular dysfunction
• Distal renal tubular acidosis in some patients

Renal injury is especially important with prolonged conventional amphotericin B therapy.

Liposomal Amphotericin

Modern lipid-associated formulations, particularly liposomal amphotericin B, generally cause less nephrotoxicity than conventional amphotericin B deoxycholate.

However, renal injury and electrolyte disturbances can still occur.

The formulation therefore matters when assessing toxicity.

Potassium and Magnesium

A major correction to the older source is that therapeutic amphotericin toxicity characteristically produces:

• Hypokalemia
• Hypomagnesemia

These abnormalities can themselves increase dysrhythmia risk.

Hyperkalemia is not the usual chronic electrolyte pattern, although acute severe cellular injury or massive administration errors can produce different abnormalities.

Amphotericin Infusion Reactions

Infusion-related reactions can include:

• Fever
• Chills/rigors
• Nausea
• Headache
• Hypotension
• Dyspnea

Rare severe infusion reactions may involve:

• Bronchospasm
• Severe hypotension
• Cardiovascular instability

Rapid or erroneous IV administration can be particularly dangerous.

“Red Man Syndrome” – Correction

The term red man syndrome is classically associated with rapid vancomycin infusion and is not the preferred description of amphotericin toxicity.

Amphotericin can certainly produce infusion-associated flushing and other reactions, but these should be described as amphotericin infusion reactions rather than equated with classic vancomycin infusion reaction.

Cardiovascular Toxicity

Severe amphotericin toxicity has been associated with:

• Hypotension
• Bradyarrhythmia
• Ventricular dysrhythmia
• Cardiac arrest

Potential contributors include:

• Electrolyte abnormalities
• Infusion-related reactions
• Severe renal dysfunction
• Administration errors

Continuous ECG monitoring is appropriate after a substantial IV overdose or when cardiovascular abnormalities develop.

Amphotericin Drug Interactions

Risk of renal injury increases when amphotericin is combined with other nephrotoxic exposures.

Examples can include:

• Aminoglycosides
• Calcineurin inhibitors
• Other nephrotoxic medications

Diuretics or other causes of potassium/magnesium loss may further increase electrolyte complications.

2. Flucytosine

Flucytosine is an antifungal antimetabolite.

Fungal cells convert it through metabolic pathways to compounds related to 5-fluorouracil, interfering with:

• DNA synthesis
• RNA function

Human cells do not efficiently perform the initial conversion, but excessive systemic exposure can still cause substantial toxicity.

Flucytosine – Major Toxicities

The main target organs are rapidly dividing tissues.

Important effects include:

• Bone-marrow suppression
• GI toxicity
• Hepatotoxicity

Possible hematologic abnormalities include:

• Leukopenia
• Neutropenia
• Thrombocytopenia
• Anemia
• Pancytopenia in severe cases

Flucytosine and Renal Function

Flucytosine is substantially eliminated by the kidneys.

Therefore:

Renal impairment → reduced clearance → accumulation → greater marrow and GI toxicity

Renal function is one of the most important determinants of toxicity during therapy.

Flucytosine GI Toxicity

Possible manifestations include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort

Severe systemic exposure can produce significant mucosal injury, but the historical description that severe GI injury is universal is too strong.

Flucytosine Concentrations

Unlike the older blanket statement that antifungal concentrations are never clinically useful, therapeutic drug monitoring can be clinically useful for flucytosine, particularly during treatment when:

• Renal function is impaired
• High exposure is suspected
• Toxicity develops

This is primarily a therapeutic-monitoring issue rather than a reason to delay acute supportive care.

3. Azole Antifungals

Azoles inhibit fungal lanosterol 14-α-demethylase, disrupting ergosterol synthesis and fungal cell membranes.

Modern systemic azoles include:

• Fluconazole
• Itraconazole
• Voriconazole
• Posaconazole
• Isavuconazole

Ketoconazole remains historically important but systemic oral use has been greatly restricted in many settings because of toxicity.

Azole Toxicity

Accidental single ingestions are often relatively mild.

Possible acute effects include:

• Nausea
• Vomiting
• Abdominal discomfort
• Headache
• Dizziness

More clinically important problems during systemic therapy include:

• Hepatotoxicity
• Drug interactions
• QT effects with several agents
• Agent-specific endocrine or neurologic effects

Azole Hepatotoxicity

Systemic azoles can cause:

• Transaminase elevation
• Hepatitis
• Rare severe hepatic injury

Risk and frequency differ among individual drugs.

Significant symptoms such as jaundice, persistent vomiting, right-upper-quadrant discomfort, or unexplained systemic illness warrant liver assessment.

Ketoconazole

Oral ketoconazole is no longer treated as a routine systemic antifungal in many modern settings because it can cause serious:

• Hepatotoxicity
• Adrenal steroid synthesis inhibition
• Drug interactions

Endocrine effects can include:

• Adrenal insufficiency
• Reduced androgen synthesis
• Gynecomastia
• Sexual/reproductive effects during prolonged exposure

Topical ketoconazole has far less systemic exposure.

Voriconazole

Voriconazole can cause distinctive adverse effects including:

• Transient visual disturbances
• Hallucinations or other neuropsychiatric effects
• Hepatotoxicity
• QT prolongation
• Photosensitivity with prolonged use

Toxicity may become more likely when concentrations rise because of nonlinear pharmacokinetics and metabolic variability.

Therapeutic drug monitoring is clinically useful in selected patients.

Itraconazole

Itraconazole can cause:

• GI symptoms
• Hepatotoxicity
• Drug interactions
• Edema
• Negative inotropic effects

It can worsen or precipitate heart failure in susceptible patients.

This cardiac adverse effect is important during therapeutic use and is not simply an overdose phenomenon.

Fluconazole

Fluconazole is generally better tolerated than many older systemic azoles.

Possible toxicity includes:

• GI symptoms
• Hepatotoxicity
• Rash
• QT prolongation

Serious skin reactions such as Stevens–Johnson syndrome are rare but recognized.

Isavuconazole – Important Exception

Most clinically important systemic azoles can prolong the QT interval.

Isavuconazole is an important exception because it tends to shorten the QT interval.

This distinction can be useful when interpreting ECG findings.

QT Prolongation

For QT-prolonging antifungals, dysrhythmia risk increases with:

• Hypokalemia
• Hypomagnesemia
• Bradycardia
• Congenital long-QT syndrome
• Other QT-prolonging drugs

Management centers on:

• Stopping the offending agent
• Correcting electrolytes
• ECG monitoring when clinically indicated

Torsades is treated with standard measures including IV magnesium and electrical therapy when unstable.

Azole Drug Interactions

Drug interactions are among the most important hazards of systemic azole therapy.

Many azoles inhibit CYP enzymes to varying degrees.

Consequently, concentrations of other medications may rise.

Clinically important interactions can involve drugs such as:

• Certain anticoagulants
• Some statins
• Calcineurin inhibitors
• Some benzodiazepines
• Antiarrhythmics
• Antiseizure medications
• Some glucose-lowering drugs

The exact interaction profile differs substantially among individual azoles.

Important Correction – CYP Statement

The older source’s broad interaction description is oversimplified.

Azoles generally act as CYP inhibitors, not simply as nonspecific agents that raise a fixed list of drug concentrations.

The affected CYP pathways and interaction magnitude vary by antifungal.

Medication-specific interaction checking is therefore important.

4. Echinocandins

Modern echinocandins include:

• Caspofungin
• Micafungin
• Anidulafungin

They inhibit fungal β-(1,3)-D-glucan synthesis, impairing the fungal cell wall.

They were not represented adequately in older antifungal toxicology references.

Echinocandin Toxicity

These agents generally have a favorable toxicity profile.

Possible adverse effects include:

• Infusion reactions
• Histamine-mediated flushing
• Rash
• GI symptoms
• Transaminase elevation

Severe acute poisoning is uncommon.

Management is mainly supportive.

5. Nystatin

Nystatin is a polyene but is poorly absorbed from intact GI mucosa and skin.

Therefore, accidental oral exposure generally causes limited systemic toxicity.

Possible effects are mainly:

• Nausea
• Vomiting
• Diarrhea

Systemic toxicity is unusual with conventional topical/oral preparations.

6. Topical and Vaginal Antifungals

Agents include various formulations of:

• Clotrimazole
• Miconazole
• Terconazole
• Tioconazole
• Nystatin

Systemic absorption from ordinary topical use is generally limited.

Adverse effects are more commonly:

• Local burning
• Irritation
• Erythema
• Contact dermatitis

Accidental small oral exposures are usually much less concerning than systemic antifungal overdoses.

Diagnosis

There is no universal antifungal poisoning syndrome.

Assessment should identify:

• Exact drug
• Formulation
• Route
• Amount
• Timing
• Acute overdose vs chronic therapeutic toxicity
• Renal function
• Hepatic function
• Interacting medications

This distinction is particularly important because many serious antifungal toxicities develop during therapeutic treatment, not after a single overdose.

Laboratory Evaluation

Testing should be drug-specific.

Amphotericin B

Consider:

• Creatinine
• BUN
• Potassium
• Magnesium
• Bicarbonate
• Calcium
• ECG when significant toxicity is suspected
• CBC during prolonged treatment

Flucytosine

Consider:

• CBC with differential
• Platelets
• Creatinine
• Liver tests
• Electrolytes

Systemic azoles

Consider:

• Liver tests
• Electrolytes
• ECG for QT-risk situations
• Renal function where relevant

Therapeutic Drug Monitoring

The older statement that antifungal levels are universally useless is incorrect.

Drug concentrations can have clinical roles for selected systemic antifungals, particularly:

• Flucytosine
• Voriconazole
• Itraconazole
• Posaconazole in selected circumstances

This is especially relevant during prolonged therapy, treatment failure, organ dysfunction, suspected toxicity, or major drug interactions.

Acute stabilization should never be delayed while waiting for a concentration.

Initial Management

General priorities are:

Airway/breathing → circulation → identify exact antifungal → ECG/electrolytes when relevant → renal/hepatic/marrow assessment → supportive care

There is no universal antidote for antifungal poisoning.

GI Decontamination

Ipecac should not be used.

Induced vomiting is obsolete in poisoning management.

Routine gastric lavage is also inappropriate.

A single dose of activated charcoal may occasionally be considered after a substantial recent ingestion of an adsorbable systemic antifungal when:

• The airway is safe
• Aspiration risk is low
• Expected benefit justifies treatment

Many accidental antifungal ingestions do not require GI decontamination.

Hypotension

Treat the cause.

Management may include:

• Appropriate isotonic crystalloid
• Treatment of severe infusion reactions
• Correction of electrolyte abnormalities
• Vasopressor support for persistent shock

Norepinephrine is generally favored for persistent vasodilatory shock.

Routine Trendelenburg positioning and a dopamine-first strategy are outdated.

Dysrhythmias

When dysrhythmias occur:

• Stop the causative drug
• Correct potassium
• Correct magnesium
• Correct significant calcium abnormalities
• Treat hypoxemia/acidemia
• Follow standard resuscitation principles

For torsades associated with QT prolongation:

• IV magnesium
• Correction of electrolytes
• Electrical treatment if unstable

Bone-Marrow Suppression

This is particularly important with flucytosine.

Monitor:

• Hemoglobin
• Leukocyte/neutrophil count
• Platelets

Clinically important marrow suppression may require:

• Discontinuation of the drug
• Supportive hematologic care
• Management of infection or bleeding complications

Recovery depends partly on exposure severity and renal clearance.

Renal Injury

Amphotericin-associated renal toxicity requires:

• Serial renal function
• Careful volume assessment
• Potassium monitoring
• Magnesium monitoring
• Review of other nephrotoxic drugs

Electrolyte abnormalities may persist even when creatinine changes are modest.

Hepatic Injury

Systemic azoles and, less commonly, other antifungals may produce clinically significant liver injury.

Evaluate significant cases with:

• AST/ALT
• Bilirubin
• Coagulation studies when severe

Severe hepatic dysfunction warrants specialist assessment.

Extracorporeal Treatment

There is no general role for dialysis simply because an antifungal overdose has occurred.

Potential usefulness depends on the specific agent and its:

• Protein binding
• Volume of distribution
• Molecular characteristics
• Renal clearance

Dialysis may still be required for conventional indications such as severe renal failure or dangerous electrolyte abnormalities.

Monitoring

Monitoring should match the causative drug.

Important parameters may include:

• Vital signs
• ECG
• Potassium
• Magnesium
• Renal function
• Liver function
• CBC
• Platelets

A patient receiving amphotericin requires a very different monitoring strategy from someone with a small accidental topical azole ingestion.

Observation and Disposition

A universal 6-hour observation period is not appropriate for every antifungal exposure.

Disposition depends on:

• Agent
• Route
• Formulation
• Amount
• Symptoms
• Organ function
• Laboratory abnormalities
• Drug interactions
• Intentional vs accidental exposure

Many small accidental topical or oral exposures can be managed conservatively, whereas significant amphotericin administration errors, marrow toxicity, hepatic injury, or cardiac abnormalities require monitored care.

Admission

Hospital management may be required for:

• Significant amphotericin overdose
• Dysrhythmia
• Important electrolyte abnormalities
• Acute kidney injury
• Persistent hypotension
• Severe vomiting/dehydration
• Significant marrow suppression
• Hepatitis
• Coagulopathy
• Severe drug interaction

ICU care is appropriate for severe cardiovascular instability or multiorgan toxicity.

Pregnancy

The old FDA A/B/C/D/X pregnancy categories are obsolete.

Antifungal selection during pregnancy depends strongly on:

• Specific agent
• Route
• Dose
• Duration
• Gestational stage
• Severity of fungal infection

The historical claim that all vaginal antifungals are automatically safe in pregnancy is too broad.

Topical azoles have extensive use in pregnancy, but treatment decisions should still be agent- and formulation-specific.

Similarly, breastfeeding recommendations cannot accurately be reduced to “avoid all azoles.”

Safeguarding

Rigid age thresholds for assuming neglect, abuse, or intentional poisoning are outdated.

Pediatric exposure should instead be assessed according to:

• Developmental capability
• Access to medication
• Exposure circumstances
• Consistency of history
• Recurrent unexplained events
• Broader safeguarding concerns

Prognosis

Most small accidental antifungal exposures have a favorable outcome.

Prognosis becomes more concerning with:

• Major amphotericin administration errors
• Severe renal injury
• Dangerous electrolyte abnormalities
• Dysrhythmias
• Severe flucytosine-associated marrow suppression
• Significant azole hepatotoxicity
• Serious drug interactions

Important Modernization of the Older Source

• Antifungals should not be divided simply into polyenes, flucytosine, and “imidazoles”; modern therapy includes triazoles, echinocandins, allylamines, and other agents.
• Amphotericin B primarily causes nephrotoxicity with potassium and magnesium wasting.
• Liposomal amphotericin generally causes less nephrotoxicity than conventional amphotericin B.
• Amphotericin infusion reactions should not simply be called “red man syndrome.”
• Flucytosine toxicity is strongly influenced by renal clearance and can cause severe marrow suppression.
• Flucytosine concentrations can be clinically useful; the blanket statement that antifungal levels have no value is incorrect.
• Selected azoles also use therapeutic drug monitoring.
• Systemic azoles can produce clinically important hepatotoxicity and CYP-mediated drug interactions.
• Several azoles can prolong QT, whereas isavuconazole characteristically shortens QT.
• Oral ketoconazole has been greatly restricted because of serious hepatic, endocrine, and interaction risks.
• Itraconazole can worsen heart failure because of negative inotropic effects.
• Modern echinocandins generally have relatively low acute toxicity.
• Nystatin has little systemic absorption with conventional oral/topical use.
• Ipecac and routine gastric lavage are obsolete.
• Trendelenburg and dopamine-first shock management are outdated.
• Observation and laboratory testing should be drug-specific, not based on a universal antifungal protocol.
• There is generally no specific antidote.

Key Points

• Antifungal toxicity varies dramatically by drug class.
• Amphotericin B → kidney injury + hypokalemia + hypomagnesemia + infusion reactions.
• Flucytosine → bone-marrow suppression + GI toxicity, especially with renal impairment.
• Systemic azoles → liver injury + major drug interactions + agent-specific cardiac effects.
• Topical agents and nystatin usually have limited systemic toxicity.
• Check ECG and electrolytes when QT-active drugs or amphotericin-related electrolyte disturbances are involved.
• Monitor CBC during significant flucytosine toxicity.
• Monitor renal function, potassium, and magnesium with amphotericin.
• Monitor liver function with clinically significant systemic azole toxicity.
• Management is predominantly supportive and agent-specific.